Creating and Maintaining a Resilient Supply Chain: Lessons Learned from a Pandemic

  • How do you define a supply chain?
    • The what, the who, the where and the how
  • Risk categorization
    • Impact, probability and detectability
  • Risk approach
    • Detection, prevention/mitigation and response
  • Near-miss lessons learned

Ken Kent
SVP, Chemical Development and Manufacturing Operations

Ken is the Senior Vice President of Chemical Development and Manufacturing Operations. He is responsible for Gilead’s entire drug substance supply and oversees process R&D functions in Foster City and Edmonton, as well as internal and outsourced manufacturing.

He played a critical role leading CDMO in sourcing ingredients and scaling up production of remdesivir drug substance, to speed up and increase production. Ken has contributed to the development and commercialization of more than 25 approved products while growing his career from developing new synthetic routes as a process chemist to increasing leadership responsibilities in cross-functional roles. He has built and led teams with a reputation for innovation, quality and safety while also fostering inclusion and career development. He joined Gilead in 1988, he is a member of the American Chemical Society and has published over 10 papers and patents on the research he has conducted at Gilead.